最近在RAS通路的有针对性的降解方面取得的进展
Zhiming Ge1,2,3, Zisheng Fan3,4,5, Wei He3,6
1School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, China.
Future medicinal chemistry
|March 11, 2025
概括
向蛋白质降解提供了一种通过降解RAS蛋白质,一种常见的癌症驱动器来对抗癌症的新方法. 这种方法可以克服耐药性,提高各种恶性瘤的治疗精度.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 在癌症中,RAS蛋白经常发生突变,通过异常信号驱动瘤生长.
- 准RAS一直是个挑战,但最近的抑制剂对特定突变有希望.
- 目前RAS抑制剂的局限性包括获得的耐药性和组合疗法毒性.
研究的目的:
- 审查针对RAS通路调节的向蛋白质降解 (TPD) 策略的进展.
- 突出TPD作为一种克服传统RAS抑制剂局限性的新方法.
- 讨论RAS降解剂在癌症治疗中的潜力.
主要方法:
- 对针对性蛋白质降解 (TPD) 策略的最新文献的审查.
- 专注于针对RAS通路组件的PROTACs和分子合剂.
- 对RAS突变,上游调节器和下游效应器的TPD方法的分析.
主要成果:
- TPD策略提供了一种新的机制来降解RAS蛋白和相关因素.
- 降解剂显示出绕过传统抑制剂所获得的耐药性的潜力.
- 通过选择性地准异常信号,TPD提高了治疗精度.
结论:
- 向蛋白质降解代表了由RAS突变驱动的癌症的有希望的治疗策略.
- RAS降解剂可以克服与当前疗法相关的耐药性和毒性问题.
- 进一步发展TPD具有促进癌症治疗的巨大潜力.
相关概念视频
The Ras Gene
6.1K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
6.1K
Small GTPases - Ras and Rho
3.9K
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Three regulatory proteins control their activity:
3.9K
MAPK Signaling Cascades
5.1K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.1K
Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K


